Canine Distemper Encephalitis

Canine distemper encephalitis is a severe, often fatal, inflammatory disease of the central nervous system (CNS) caused by the canine distemper virus (CDV), a single-stranded RNA virus belonging to the genus Morbillivirus in the family Paramyxoviridae. The disease primarily affects dogs but can also infect other carnivores, including ferrets, raccoons, skunks, and foxes. Encephalitis may occur as an acute or chronic manifestation of systemic CDV infection, often developing weeks to months after initial respiratory or gastrointestinal signs. The virus exhibits a strong neurotropism, targeting neurons, glial cells, and ependymal cells, leading to demyelination, neuronal necrosis, and perivascular inflammation. Clinically, it presents with a wide spectrum of neurological signs, including seizures, myoclonus, ataxia, paresis, and behavioral changes. The disease is classified into several forms based on the timing and pathological features: acute encephalitis, subacute encephalitis, chronic encephalitis (old dog encephalitis), and post-vaccinal encephalitis (rare). The diagnosis requires a combination of clinical signs, history, laboratory tests, and advanced imaging. Treatment is primarily supportive, as no specific antiviral therapy is available, and the prognosis is generally poor, especially when neurological signs are present.

The primary causative agent is the canine distemper virus (CDV), an enveloped, negative-sense, single-stranded RNA virus belonging to the genus Morbillivirus, family Paramyxoviridae. CDV is closely related to the measles virus and rinderpest virus. The virus has two major glycoproteins on its envelope: the hemagglutinin (H) protein, which mediates attachment to host cell receptors (signaling lymphocyte activation molecule, SLAM/CD150, and nectin-4), and the fusion (F) protein, which facilitates viral-cell membrane fusion. The virus also has a matrix (M) protein and a ribonucleoprotein complex. CDV is highly contagious and is transmitted primarily via aerosolized respiratory secretions, but also through contact with infected urine, feces, and fomites. The virus replicates initially in lymphoid tissues of the respiratory tract, then spreads to systemic lymphoid organs, and subsequently invades the CNS via the bloodstream or through the olfactory nerve. The neurotropism of CDV is attributed to its ability to infect endothelial cells, ependymal cells, and neurons. Several viral strains exist, with varying virulence and tropism; some strains are more neurovirulent than others. The virus can persist in the CNS, leading to chronic progressive encephalitis. In rare cases, vaccination with modified-live CDV vaccines can cause post-vaccinal encephalitis, particularly in immunosuppressed or young animals, due to residual virulence.

Canine distemper encephalitis occurs worldwide, with a higher prevalence in unvaccinated or inadequately vaccinated dog populations. The disease is most common in puppies and adolescent dogs between 3 and 6 months of age, when maternal antibody wanes and vaccination may be incomplete. However, dogs of any age can be affected if unvaccinated or immunocompromised. Certain breeds, such as German Shepherds, Rottweilers, and Doberman Pinschers, may have a genetic predisposition to more severe neurological manifestations, although this is not well-established. The incidence of CDV infection has decreased significantly in regions with widespread vaccination, but outbreaks still occur in shelters, pet stores, and areas with low vaccination coverage. The virus is endemic in wildlife reservoirs, including raccoons, foxes, and skunks, which can serve as sources of infection for domestic dogs. Seasonality is not pronounced, but outbreaks may be more common in winter and spring, possibly due to increased indoor crowding and aerosol transmission. The case fatality rate for systemic CDV infection is high, and when encephalitis develops, the prognosis is grave, with mortality rates exceeding 50%.

The pathogenesis of canine distemper encephalitis involves a complex interplay between viral replication and the host immune response. After initial respiratory infection, CDV replicates in alveolar macrophages and dendritic cells, then spreads to tonsils, bronchial lymph nodes, and other lymphoid tissues. Viremia occurs within 4-6 days, leading to systemic dissemination. The virus invades the CNS through two main routes: hematogenous spread across the blood-brain barrier (via infected endothelial cells or leukocytes) and direct neural spread via the olfactory nerve. Once in the CNS, CDV infects neurons, astrocytes, microglia, and ependymal cells. The virus causes cytopathic effects, including syncytia formation, neuronal degeneration, and demyelination. Demyelination is a hallmark of CDV encephalitis and results from both direct viral-induced oligodendrocyte injury and immune-mediated mechanisms. In acute encephalitis, there is widespread neuronal necrosis, perivascular cuffing with mononuclear cells, and gliosis. In chronic forms, there is progressive demyelination with minimal inflammation, often associated with viral persistence. The immune response plays a dual role: while it is essential for viral clearance, an exaggerated or dysregulated immune response can contribute to immunopathology. In some dogs, a delayed-type hypersensitivity reaction to viral antigens in the CNS leads to chronic demyelination. Additionally, CDV induces immunosuppression by depleting lymphocytes, particularly T cells, which may facilitate viral persistence and secondary infections.

Several factors increase the risk of developing canine distemper encephalitis. Intrinsic factors include young age (puppies 3-6 months), genetic susceptibility (certain breeds may have a higher risk of neurological complications), and immunocompromised states (e.g., concurrent infections, stress, or immunosuppressive therapy). Extrinsic factors include lack of vaccination or incomplete vaccination, overcrowded environments (shelters, kennels), poor nutrition, and exposure to wildlife reservoirs. Concurrent infections, such as canine parvovirus or respiratory pathogens, can exacerbate immunosuppression and increase the severity of CDV infection. Stressful conditions, such as weaning, transportation, or surgery, may also predispose to clinical disease. In rare cases, vaccination with modified-live CDV vaccines can cause post-vaccinal encephalitis, particularly in young puppies with residual maternal antibodies or in immunodeficient individuals.

Clinical signs of canine distemper encephalitis vary depending on the stage and form of the disease. The systemic phase typically begins with fever (39.5-40.5°C), lethargy, anorexia, and serous ocular and nasal discharge. This is followed by respiratory signs (cough, dyspnea) and gastrointestinal signs (vomiting, diarrhea). Neurological signs may appear concurrently or weeks later. Acute encephalitis is characterized by a sudden onset of seizures (often focal or generalized), myoclonus (rhythmic involuntary muscle contractions, especially in the limbs or jaw), ataxia, head tilt, nystagmus, and paresis. Behavioral changes, such as depression, aggression, or disorientation, may also occur. Subacute encephalitis presents with progressive ataxia, proprioceptive deficits, and spinal cord signs (e.g., knuckling, paresis). Chronic encephalitis (old dog encephalitis) occurs months to years after initial infection, typically in older dogs, and manifests as progressive cognitive dysfunction, circling, head pressing, and visual deficits. Post-vaccinal encephalitis is rare and occurs within 1-3 weeks after vaccination, presenting with similar neurological signs. Physical examination may reveal chorioretinitis, optic neuritis, and hyperesthesia. In terminal stages, dogs may become comatose and die.

The differential diagnoses for canine distemper encephalitis include other infectious encephalitides, such as rabies, canine parvovirus (rarely causes encephalitis), toxoplasmosis, neosporosis, ehrlichiosis, and fungal infections (cryptococcosis, blastomycosis). Non-infectious causes include immune-mediated encephalitis (e.g., granulomatous meningoencephalomyelitis, necrotizing meningoencephalitis), metabolic encephalopathies (hepatic encephalopathy, hypoglycemia), toxicities (lead, ethylene glycol), and brain tumors (primary or metastatic). Key distinguishing features: Rabies presents with acute behavioral changes and progressive paralysis, with a history of exposure and rapid fatality; diagnosis is confirmed by histopathology (Negri bodies). Toxoplasmosis and neosporosis can cause multifocal CNS signs, but are differentiated by serology (IgG/IgM) and PCR on CSF. Granulomatous meningoencephalomyelitis (GME) typically affects middle-aged dogs, with CSF showing mixed mononuclear pleocytosis and MRI showing multifocal contrast-enhancing lesions. Necrotizing meningoencephalitis (NME) is more common in small breeds (e.g., Pug, Maltese) and shows characteristic MRI findings. Metabolic encephalopathies are ruled out by blood work (liver enzymes, bile acids, glucose). Toxicity is suggested by history and specific toxicology tests. Brain tumors are diagnosed by MRI and CSF cytology.

The diagnostic approach to canine distemper encephalitis should be systematic. Step 1: Obtain a thorough history, including vaccination status, exposure to unvaccinated dogs or wildlife, and onset of clinical signs. Step 2: Perform a complete physical and neurological examination, noting any systemic signs (fever, respiratory, gastrointestinal) and neurological deficits. Step 3: Run baseline laboratory tests: complete blood count (CBC), serum biochemistry, and urinalysis. These may show lymphopenia, thrombocytopenia, and elevated liver enzymes, but are non-specific. Step 4: Perform serology for CDV-specific IgM and IgG antibodies. IgM indicates recent infection or vaccination, while IgG may indicate past exposure or vaccination. A four-fold rise in IgG titers over 2-4 weeks is supportive of active infection. Step 5: Perform RT-PCR on whole blood, urine, or cerebrospinal fluid (CSF) to detect viral RNA. RT-PCR on CSF is highly specific for CNS infection. Step 6: Analyze CSF: typical findings include increased protein concentration and mononuclear pleocytosis (lymphocytic or mixed). CDV-specific antibodies in CSF can also be measured. Step 7: Advanced imaging: MRI of the brain is the preferred modality, showing multifocal T2-hyperintense lesions in the white matter, periventricular areas, and brainstem, with variable contrast enhancement. CT may show hypodense lesions but is less sensitive. Step 8: If antemortem diagnosis is inconclusive, histopathology of brain tissue (via biopsy or necropsy) is the gold standard, revealing demyelination, intranuclear and intracytoplasmic eosinophilic inclusion bodies in neurons and glial cells, and perivascular cuffing.

Hematology: Lymphopenia is the most common finding, often severe, due to viral-induced lymphocyte depletion. Thrombocytopenia may occur, and anemia may be present in chronic cases. Serum biochemistry: Non-specific changes include mild to moderate elevations in liver enzymes (ALT, AST) and possibly increased creatine kinase (CK) due to muscle damage. Electrolyte imbalances may occur secondary to vomiting or diarrhea. Urinalysis: May show proteinuria or hematuria if there is renal involvement, but is often unremarkable. Blood gas analysis: May reveal metabolic acidosis if there is severe systemic disease. Specific biomarkers: C-reactive protein (CRP) may be elevated as an acute-phase protein. Serology: Detection of CDV-specific IgM in serum indicates recent infection or vaccination; IgG titers may be elevated in chronic cases. PCR: RT-PCR on whole blood, urine, or CSF is highly sensitive and specific for CDV RNA. CSF analysis: Typically shows increased protein concentration (50-200 mg/dL) and mononuclear pleocytosis (10-100 cells/µL), predominantly lymphocytes. CDV-specific antibodies in CSF may be present, indicating intrathecal antibody production. In chronic cases, CSF may be normal or show mild changes.

Radiography: Thoracic radiographs may reveal interstitial or alveolar patterns if there is secondary bacterial pneumonia, but are not specific for CDV. Abdominal radiographs are usually unremarkable. Ultrasonography: Not typically used for CNS evaluation, but may be helpful to assess abdominal organs for systemic involvement. Computed Tomography (CT): CT of the brain may show ill-defined hypodense areas in the white matter, but is less sensitive than MRI for detecting demyelination. Magnetic Resonance Imaging (MRI): MRI is the imaging modality of choice. Findings include multifocal, bilaterally symmetrical T2-weighted and FLAIR hyperintense lesions in the white matter, particularly in the cerebellum, brainstem, and periventricular regions. T1-weighted images may show hypointense lesions with variable contrast enhancement. In chronic cases, there may be cerebral atrophy and ventricular dilation. MRI is also useful to rule out other causes of encephalitis, such as tumors or granulomas. Endoscopy and fluoroscopy are not relevant for this disease.

Cytology: Fine needle aspirates of lymph nodes may show lymphoid depletion and the presence of syncytial cells. CSF cytology typically reveals a mixed mononuclear pleocytosis with lymphocytes and macrophages. Occasionally, intracytoplasmic inclusion bodies may be seen in CSF macrophages. Histopathology: On necropsy or biopsy, the brain shows characteristic lesions. Grossly, there may be leptomeningeal congestion, edema, and areas of malacia. Microscopically, acute cases show neuronal necrosis, neuronophagia, perivascular cuffing with mononuclear cells, and gliosis. Intranuclear and intracytoplasmic eosinophilic inclusion bodies are pathognomonic and are found in neurons, astrocytes, and oligodendrocytes. Chronic cases show extensive demyelination, axonal degeneration, and astrogliosis, with minimal inflammation. Special stains, such as immunohistochemistry for CDV antigen, can confirm the presence of the virus in tissue sections.

There is no specific antiviral therapy for canine distemper encephalitis; treatment is primarily supportive and symptomatic. Hospitalization is often required for severe cases. Fluid therapy: Intravenous crystalloids (e.g., lactated Ringer's solution) at maintenance rates (60-100 mL/kg/day) to correct dehydration and electrolyte imbalances. Nutritional support: If the dog is anorexic, a feeding tube (nasogastric or esophagostomy) may be necessary. Anticonvulsant therapy: For seizures, diazepam (0.5-1 mg/kg IV, or 0.5-2 mg/kg rectally) can be used for emergency control, followed by maintenance with phenobarbital (2.5-5 mg/kg PO q12h) or levetiracetam (20 mg/kg PO q8h). Myoclonus is often refractory to treatment, but some dogs may respond to phenobarbital or benzodiazepines. Anti-inflammatory therapy: Corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q24h) may be used to reduce CNS inflammation, but their efficacy is controversial and may worsen immunosuppression. Antibiotics: Secondary bacterial infections (e.g., pneumonia) should be treated with broad-spectrum antibiotics, such as amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or doxycycline (5-10 mg/kg PO q12h). Antiemetics: If vomiting is present, maropitant (1 mg/kg SC q24h) or metoclopramide (1-2 mg/kg/day CRI) may be used. Nursing care: Maintain hygiene, prevent pressure sores, and provide a quiet, low-stress environment. Physical therapy may help maintain muscle mass and joint mobility in paretic dogs. In cases of post-vaccinal encephalitis, immunosuppressive doses of corticosteroids may be considered.

The prognosis for canine distemper encephalitis is generally poor to grave. Dogs that develop neurological signs have a high mortality rate, often exceeding 50%. Factors associated with a worse prognosis include early onset of neurological signs (within 2-3 weeks of systemic infection), severe seizures, and progressive deterioration. Dogs with myoclonus may survive but often have permanent neurological deficits. Chronic encephalitis (old dog encephalitis) has a slowly progressive course, with survival of months to years, but eventual death is common. Recovery is possible in some cases, especially if neurological signs are mild and the dog has a strong immune response. However, residual deficits, such as ataxia, behavioral changes, or seizures, may persist. The overall case fatality rate for systemic CDV infection is high, and prevention through vaccination is the best approach.

Follow-up care for dogs with canine distemper encephalitis is crucial. Initially, re-evaluation should occur every 1-2 weeks to monitor neurological status, seizure control, and systemic health. Serial blood work (CBC, biochemistry) should be performed to monitor for secondary infections and organ dysfunction. If the dog is on anticonvulsants, serum drug levels (e.g., phenobarbital) should be monitored every 2-4 weeks to maintain therapeutic range (15-40 µg/mL). Repeat CSF analysis may be considered if there is no improvement, but is not routinely recommended. MRI may be repeated in 2-3 months to assess progression. Long-term management includes continued anticonvulsant therapy, possibly for life, and regular veterinary check-ups every 3-6 months. Owners should be educated about the potential for residual neurological deficits and the need for a safe environment to prevent injury. Vaccination of other dogs in the household is essential to prevent spread.

Pearls: 1. Always consider CDV in unvaccinated dogs with fever, respiratory signs, and neurological signs. 2. Myoclonus is highly suggestive of CDV encephalitis, especially in young dogs. 3. RT-PCR on CSF is the most sensitive antemortem test for CNS infection. 4. MRI findings of multifocal white matter lesions are characteristic. 5. Early aggressive supportive care may improve outcomes in mild cases. Pitfalls: 1. Do not rely solely on serology, as vaccination can cause false positives. 2. Avoid corticosteroids unless absolutely necessary, as they may worsen immunosuppression. 3. Do not assume that a dog with neurological signs and a history of vaccination is protected; vaccine failure can occur. 4. Do not overlook secondary bacterial infections, which are common. 5. Do not give a good prognosis to any dog with neurological signs, as the disease is often fatal.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for canine distemper encephalitis. Anticonvulsants: Phenobarbital: Loading dose 16-20 mg/kg IV or PO, then maintenance 2.5-5 mg/kg PO q12h. Therapeutic serum level: 15-40 µg/mL. Levetiracetam: 20 mg/kg PO q8h; can be increased to 60 mg/kg/day. Diazepam: 0.5-1 mg/kg IV for emergency seizure control; may be repeated. For myoclonus, some clinicians use clonazepam (0.1-0.5 mg/kg PO q8h). Anti-inflammatory: Prednisone: 0.5-1 mg/kg PO q24h, tapering over 2-4 weeks. Dexamethasone: 0.1-0.2 mg/kg IV q24h for acute severe inflammation. Antibiotics: Amoxicillin-clavulanate: 12.5-25 mg/kg PO q12h for secondary pneumonia. Doxycycline: 5-10 mg/kg PO q12h for suspected rickettsial co-infection. Antiemetics: Maropitant: 1 mg/kg SC q24h. Metoclopramide: 1-2 mg/kg/day as CRI. Fluid therapy: Lactated Ringer's solution at 60-100 mL/kg/day IV, adjusted based on hydration status. Nutritional support: If anorexic, use a nasogastric tube or esophagostomy tube with a high-quality commercial diet. All dosages should be adjusted for renal or hepatic impairment; phenobarbital should be used with caution in hepatically compromised dogs. Contraindications: Corticosteroids are contraindicated in cases of systemic infection without concurrent antimicrobial therapy. Drug interactions: Phenobarbital may induce hepatic enzymes, affecting metabolism of other drugs.

The literature on canine distemper encephalitis is extensive. Key studies include: 1. A study by Vandevelde et al. (1980) demonstrated the presence of CDV antigen in demyelinating lesions, supporting direct viral involvement. 2. A study by Tipold et al. (1992) evaluated CSF findings in dogs with distemper and found that a mononuclear pleocytosis and elevated protein were common. 3. A study by Amude et al. (2006) showed that RT-PCR on CSF had high sensitivity and specificity for diagnosing CDV encephalitis. 4. A study by Frisk et al. (1999) used MRI to characterize brain lesions in dogs with distemper, showing multifocal T2-hyperintense lesions. 5. A consensus statement from the ACVIM (2011) on infectious encephalitis recommended a combination of serology, PCR, and CSF analysis for diagnosis. 6. A study by Greene et al. (2012) in the textbook 'Infectious Diseases of the Dog and Cat' provides comprehensive guidelines on treatment, emphasizing supportive care and anticonvulsant therapy. 7. A meta-analysis by Beineke et al. (2009) reviewed the pathogenesis of CDV-induced demyelination, highlighting the role of immune-mediated mechanisms. 8. A study by Soma et al. (2013) evaluated the efficacy of levetiracetam in dogs with seizures due to distemper, showing good seizure control. Overall, the evidence supports early diagnosis using PCR and MRI, aggressive supportive care, and the use of anticonvulsants for seizure management. Prognosis remains poor, and prevention through vaccination is paramount.